Nanostructure-initiator mass spectrometry (NIMS) imaging of brain cholesterol metabolites in Smith-Lemli-Opitz syndrome

Neuroscience

Volumn 170, Issue 3, 2010, Pages 858-864

  Patti, G J ^a   Shriver, L P ^b   Wassif, C A ^c   Woo, H K ^a   Uritboonthai, W ^a   Apon, J ^a   Manchester, M ^b   Porter, F D ^c   Siuzdak, G ^a  

^a SCRIPPS RESEARCH   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Brain imaging; Cholesterol; Mass spectrometry; Metabolism; Nanostructure initiator mass spectrometry; Smith Lemli Opitz syndrome

Indexed keywords

7 DEHYDROCHOLESTEROL; CHOLESTEROL; DESMOSTEROL; MAGNESIUM ION;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; BRAIN STEM; CEREBELLUM; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; EMBRYO; IMAGE ANALYSIS; IN SITU HYBRIDIZATION; MASS SPECTROMETRY; MOUSE; NANOSTRUCTURE INITIATOR MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; SMITH LEMLI OPITZ SYNDROME;

ANIMALS; BRAIN; CHOLESTEROL; DISEASE MODELS, ANIMAL; MASS SPECTROMETRY; MICE; MICE, MUTANT STRAINS; NANOTECHNOLOGY; SMITH-LEMLI-OPITZ SYNDROME;

EID: 79551519681     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2010.07.038     Document Type: Article

References (44)

1. Aneja A., Tierney E. Autism: the role of cholesterol in treatment. Int Rev Psychiatry 2008, 20:165-170.
2. Bjorkhem I, Leoni V, Meaney S (in press) Genetic connections between neurological disorders and cholesterol metabolism. J Lipid Res, in press.
3. Bjorkhem I., Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol 2004, 24:806-815.
4. Buitelaar J.K., Willemsen-Swinkels S.H. Autism: current theories regarding its pathogenesis and implications for rational pharmacotherapy. Paediatr Drugs 2000, 2:67-81.
5. Chugani D.C., Muzik O., Rothermel R., Behen M., Chakraborty P., Mangner T., da Silva E.A., Chugani H.T. Altered serotonin synthesis in the dentatothalamocortical pathway in autistic boys. Ann Neurol 1997, 42:666-669.
6. Cooper M.K., Wassif C.A., Krakowiak P.A., Taipale J., Gong R., Kelley R.I., Porter F.D., Beachy P.A. A defective response to Hedgehog signaling in disorders of cholesterol biosynthesis. Nat Genet 2003, 33:508-513.
7. Correa-Cerro L.S., Porter F.D. 3beta-hydroxysterol Delta7-reductase and the Smith-Lemli-Opitz syndrome. Mol Genet Metab 2005, 84:112-126.
8. Daniels T.F., Killinger K.M., Michal J.J., Wright R.W., Jiang Z. Lipoproteins, cholesterol homeostasis and cardiac health. Int J Biol Sci 2009, 5:474-488.
9. Dietschy J.M. Central nervous system: cholesterol turnover, brain development and neurodegeneration. Biol Chem 2009, 390:287-293.
10. Fitzky B.U., Witsch-Baumgartner M., Erdel M., Lee J.N., Paik Y.K., Glossmann H., Utermann G., Moebius F.F. Mutations in the Delta7-sterol reductase gene in patients with the Smith-Lemli-Opitz syndrome. Proc Natl Acad Sci U S A 1998, 95:8181-8186.
11. Frantz I.D., Schroepfer G.J. Sterol biosynthesis. Annu Rev Biochem 1967, 36:691-726.
12. Hanley H.G., Stahl S.M., Freedman D.X. Hyperserotonemia and amine metabolites in autistic and retarded children. Arch Gen Psychiatry 1977, 34:521-531.
13. Hatten M.E., Alder J., Zimmerman K., Heintz N. Genes involved in cerebellar cell specification and differentiation. Curr Opin Neurobiol 1997, 7:40-47.
14. Igarashi M., Suzuki K., Chen S.M. Changes in brain hydrolytic enzyme activities in rats treated with cholesterol biosynthesis inhibitor, AY9944. Brain Res 1975, 90:97-114.
15. Jiang X.S., Wassif C.A., Backlund P.S., Song L., Holtzclaw L.A., Li Z., Yergey A.L., Porter F.D. Activation of Rho GTPases in Smith-Lemli-Opitz syndrome: pathophysiological and clinical implications. Hum Mol Genet 2010, 19:1347-1357.
16. Kandutsch A.A., Russell A.E. Preputial gland tumor sterols. 3. A metabolic pathway from lanosterol to cholesterol. J Biol Chem 1960, 235:2256-2261.
17. Kelley R.I. Diagnosis of Smith-Lemli-Opitz syndrome by gas chromatography/mass spectrometry of 7-dehydrocholesterol in plasma, amniotic fluid and cultured skin fibroblasts. Clin Chim Acta 1995, 236:45-58.
18. Kelley R.I., Hennekam R.C. The Smith-Lemli-Opitz syndrome. J Med Genet 2000, 37:321-335.
19. Kelley R.I., Herman G.E. Inborn errors of sterol biosynthesis. Annu Rev Genomics Hum Genet 2001, 2:299-341.
20. Kolsch H., Heun R., Jessen F., Popp J., Hentschel F., Maier W., Lutjohann D. Alterations of cholesterol precursor levels in Alzheimer's disease. Biochim Biophys Acta 2010, 1801:945-950.
21. Korade Z., Kenworthy A.K., Mirnics K. Molecular consequences of altered neuronal cholesterol biosynthesis. J Neurosci Res 2009, 87:866-875.
22. Lanoue L., Dehart D.B., Hinsdale M.E., Maeda N., Tint G.S., Sulik K.K. Limb, genital, CNS, and facial malformations result from gene/environment-induced cholesterol deficiency: further evidence for a link to sonic hedgehog. Am J Med Genet 1997, 73:24-31.
23. Liu J.P., Tang Y., Zhou S., Toh B.H., McLean C., Li H. Cholesterol involvement in the pathogenesis of neurodegenerative diseases. Mol Cell Neurosci 2010, 43:33-42.
24. Maxfield F.R., Tabas I. Role of cholesterol and lipid organization in disease. Nature 2005, 438:612-621.
25. Northen T.R., Yanes O., Northen M.T., Marrinucci D., Uritboonthai W., Apon J., Golledge S.L., Nordstrom A., Siuzdak G. Clathrate nanostructures for mass spectrometry. Nature 2007, 449:1033-1036.
26. Patti G.J., Woo H.K., Yanes O., Shriver L., Thomas D., Uritboonthai W., Apon J.V., Steenwyk R., Manchester M., Siuzdak G. Detection of carbohydrates and steroids by cation-enhanced nanostructure-initiator mass spectrometry (NIMS) for biofluid analysis and tissue imaging. Anal Chem 2010, 82:121-128.
27. Porter F.D. Human malformation syndromes due to inborn errors of cholesterol synthesis. Curr Opin Pediatr 2003, 15:607-613.
28. Porter F.D. Smith-Lemli-Opitz syndrome: pathogenesis, diagnosis and management. Eur J Hum Genet 2008, 16:535-541.
29. Porter J.A., Young K.E., Beachy P.A. Cholesterol modification of hedgehog signaling proteins in animal development. Science 1996, 274:255-259.
30. Rajanikant G.K., Zemke D., Kassab M., Majid A. The therapeutic potential of statins in neurological disorders. Curr Med Chem 2007, 14:103-112.
31. Scanlon S.M., Williams D.C., Schloss P. Membrane cholesterol modulates serotonin transporter activity. Biochemistry 2001, 40:10507-10513.
32. Scott M.M., Deneris E.S. Making and breaking serotonin neurons and autism. Int J Dev Neurosci 2005, 23:277-285.
33. Sikora D.M., Pettit-Kekel K., Penfield J., Merkens L.S., Steiner R.D. The near universal presence of autism spectrum disorders in children with Smith-Lemli-Opitz syndrome. Am J Med Genet A 2006, 140:1511-1518.
34. Tierney E., Nwokoro N.A., Porter F.D., Freund L.S., Ghuman J.K., Kelley R.I. Behavior phenotype in the RSH/Smith-Lemli-Opitz syndrome. Am J Med Genet 2001, 98:191-200.
35. Tint G.S., Yu H., Shang Q., Xu G., Patel S.B. The use of the Dhcr7 knockout mouse to accurately determine the origin of fetal sterols. J Lipid Res 2006, 47:1535-1541.
36. Vaillant C., Monard D. SHH pathway and cerebellar development. Cerebellum 2009, 8:291-301.
37. Waage-Baudet H., Lauder J.M., Dehart D.B., Kluckman K., Hiller S., Tint G.S., Sulik K.K. Abnormal serotonergic development in a mouse model for the Smith-Lemli-Opitz syndrome: implications for autism. Int J Dev Neurosci 2003, 21:451-459.
38. Wassif C.A., Maslen C., Kachilele-Linjewile S., Lin D., Linck L.M., Connor W.E., Steiner R.D., Porter F.D. Mutations in the human sterol delta7-reductase gene at 11q12-13 cause Smith-Lemli-Opitz syndrome. Am J Hum Genet 1998, 63:55-62.
39. Wassif C.A., Zhu P., Kratz L., Krakowiak P.A., Battaile K.P., Weight F.F., Grinberg A., Steiner R.D., Nwokoro N.A., Kelley R.I., Stewart R.R., Porter F.D. Biochemical, phenotypic and neurophysiological characterization of a genetic mouse model of RSH/Smith-Lemli-Opitz syndrome. Hum Mol Genet 2001, 10:555-564.
40. Waterham H.R., Wijburg F.A., Hennekam R.C., Vreken P., Poll-The B.T., Dorland L., Duran M., Jira P.E., Smeitink J.A., Wevers R.A., Wanders R.J. Smith-Lemli-Opitz syndrome is caused by mutations in the 7-dehydrocholesterol reductase gene. Am J Hum Genet 1998, 63:329-338.
41. Woo H.K., Northen T.R., Yanes O., Siuzdak G. Nanostructure-initiator mass spectrometry: a protocol for preparing and applying NIMS surfaces for high-sensitivity mass analysis. Nat Protoc 2008, 3:1341-1349.
42. Xu L., Korade Z., Porter N.A. Oxysterols from free radical chain oxidation of 7-dehydrocholesterol: product and mechanistic studies. J Am Chem Soc 2010, 132:2222-2232.
43. Yu H., Li M., Tint G.S., Chen J., Xu G., Patel S.B. Selective reconstitution of liver cholesterol biosynthesis promotes lung maturation but does not prevent neonatal lethality in Dhcr7 null mice. BMC Dev Biol 2007, 7:27.
44. Yu H., Wessels A., Tint G.S., Patel S.B. Partial rescue of neonatal lethality of Dhcr7 null mice by a nestin promoter-driven DHCR7 transgene expression. Brain Res Dev Brain Res 2005, 156:46-60.